Detalhe da pesquisa
1.
Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression.
Mol Cell
; 82(18): 3333-3349.e9, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35981542
2.
The pan-RAF-MEK non degrading molecular glue NST-628 is a potent and brain penetrant inhibitor of the RAS-MAPK pathway with activity across diverse RAS- and RAF-driven cancers.
Cancer Discov
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38588399
3.
KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy.
Cell Rep
; 39(12): 110993, 2022 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35732135
4.
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.
Cancer Discov
; 11(8): 1913-1922, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33824136
5.
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
Cell Rep
; 37(9): 110060, 2021 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34852220
6.
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition.
Clin Cancer Res
; 26(7): 1633-1643, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31776128
7.
WNT Activates the AAK1 Kinase to Promote Clathrin-Mediated Endocytosis of LRP6 and Establish a Negative Feedback Loop.
Cell Rep
; 26(1): 79-93.e8, 2019 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30605688
8.
Therapeutic strategies to target RAS-mutant cancers.
Nat Rev Clin Oncol
; 15(11): 709-720, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30275515
9.
ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.
Mol Cancer Res
; 14(10): 1009-1018, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27418645
10.
Targeting RAS-mutant cancers: is ERK the key?
Trends Cancer
; 1(3): 183-198, 2015 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26858988